LSM

Cedar Point's record-breaking Top Thrill 2™ roller coaster opens Saturday

Retrieved on: 
Dienstag, April 30, 2024
Diving, CP, Weightlessness, Millennium Force, LSM, Magnum, Amusement park

The "strata" coaster, known as any roller coaster eclipsing a height of 400 feet, was first pioneered by Cedar Point in 2003.

Key Points: 
  • The "strata" coaster, known as any roller coaster eclipsing a height of 400 feet, was first pioneered by Cedar Point in 2003.
  • "Cedar Point has a long-lasting legacy of record-breaking roller coaster innovation and Top Thrill 2 delivers everything a thrill-seeker could want, including staggering height and speed," said Carrie Boldman, vice president and general manager of Cedar Point.
  • Cedar Point is the industry leader in roller coaster innovation, having introduced some of the tallest and fastest rides on the planet.
  • For more information on Top Thrill 2 and to view Cedar Point's operating calendar, guests can visit cedarpoint.com .

Liberty Mutual Insurance Strengthens Global Capabilities and Operating Model to Embrace Future Opportunities in Asia Pacific and Surety Businesses

Retrieved on: 
Mittwoch, April 17, 2024
P&C, Surety, Insurance, Knowledge, GRS, Environment, Liberty Mutual, LII, MENA, LSM, Liberty, Growth

The announcement includes the creation of a new international insurance business division, the unification of two business operations in Asia and the evolution of the company's global surety model. These strategic choices allow GRS to further enable global capabilities through local execution -- all in service of meeting the evolving needs of clients and broker partners.

Key Points: 
  • The announcement includes the creation of a new international insurance business division, the unification of two business operations in Asia and the evolution of the company's global surety model.
  • GRS will create Liberty International Insurance (LII), which will continue to go to market in Asia Pacific, Europe, Latin America and the UK & MENA under its existing brands, including Liberty Specialty Markets (LSM) and Liberty Insurance.
  • Matthew Jackson, currently Head of Asia for Liberty Specialty Markets, will be named President, Liberty International Insurance, Asia Pacific.
  • As a result of this new operating model, Liberty Mutual Surety can better leverage its talent to provide surety customers worldwide with more product expertise and value-added services.

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

Retrieved on: 
Montag, April 8, 2024
Biotechnology, Men, Health, Consumer, Other Health, Pharmaceutical, Surgery, Other Science, Research, Medical Devices, Science, Women, Seniors, Clinical Trials, Week, Sciatica, LDH, Incidence, Ferring Pharmaceuticals, Patient, Spinal disc herniation, Șaeș, University, ESI, Quality of life, Manager, University of Illinois Urbana-Champaign, Society, Back pain, LSM, Pain, SAE

"Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."

Key Points: 
  • "Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."
  • An analysis assessing current treatment patterns and gaps in clinical management of patients with newly diagnosed LDH was also presented.
  • The analysis reviewed medical claims data of more than a million U.S. patients over a four-year period.
  • Among patients who received more than one ESI, one in five (22.4%) underwent surgery with 14.2% of those patients receiving repeated surgeries.

Ace Vision Group Names Ken Araki to Its Board of Directors

Retrieved on: 
Freitag, April 5, 2024
Takeda Pharmaceutical Company, Presbyopia, Patient, Quality of life, Eye, LSM, FDA, Ageing, Ophthalmology, Pharmaceutical industry

BOSTON, April 5, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors.

Key Points: 
  • BOSTON, April 5, 2024 /PRNewswire/ -- Ace Vision Group, Inc ., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors.
  • Mr. Araki brings executive management experience and strategic leadership skills to support and drive commercial planning for the VisioLite® laser.
  • "As we prepare for commercialization of this ground-breaking ophthalmic laser therapeutic for the age-related vision loss that comes with presbyopia, Ken is an important addition to our team," said Dr. AnnMarie Hipsley, CEO of Ace Vision Group.
  • "I look forward to working with Ace Vision Group to offer new and innovative solutions for presbyopia," said Araki.

Liver-Assessment Tool Hepatoscope® Cleared for Use in U.S. and Europe Just as First Medication for MASH* Gains FDA Approval

Retrieved on: 
Dienstag, März 26, 2024
Software, Research, General Health, Medical Devices, Technology, Healthcare Reform, Science, Other Technology, FDA, Other Science, Health, Public Policy, Government, Diagnosis, Scripps Center, School corporal punishment, CE, Liver disease, Disease, Associate, Physician, F2, Risk, Cirrhosis, Patient, Syndrome, F3, Triage, Tool, Death, MASH, Fibrosis, LSM, Use, Multimedia, Hepatocellular carcinoma, Liver, Food, Medical imaging

This is a timely and exciting development in the fight against metabolism-related liver disease, which is on the rise globally.

Key Points: 
  • This is a timely and exciting development in the fight against metabolism-related liver disease, which is on the rise globally.
  • The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually.
  • “Medication that can reverse some of the worst impacts of MASH will be a huge help to our patients.
  • Questions of access matter more than ever,” he concluded, “as patients stand to benefit from these newer, more effective forms of treatment.”

Professor Marshall Continues to Propel Ace Vision Group Forward

Retrieved on: 
Donnerstag, April 4, 2024
Retina, Food and Drug Administration, Presbyopia, Approximation error, Diabetes, Patient, Public, Light, Research, Doctor of Philosophy, University College London, Eye, LSM, Sclera, Food, FDA, Ageing, Telescopic sight

BOSTON, April 4, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named John Marshall, PhD, FRCPath, FMedSc as Scientific Advisor of Laser Technology.

Key Points: 
  • Ace Vision Group Names Renown Eye Laser Pioneer John Marshall, PhD, FRCPath, FMedSc as Scientific Advisor of Laser Technology
    BOSTON, April 4, 2024 /PRNewswire/ -- Ace Vision Group, Inc ., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named John Marshall, PhD, FRCPath, FMedSc as Scientific Advisor of Laser Technology.
  • Professor Marshall is a pioneer of laser eye surgery, having developed computer-controlled excimer lasers for the correction of human refractive errors, creating a new field of eye surgery.
  • "We are honored to add Professor Marshall who is so central in the field of eye lasers," said Dr. AnnMarie Hipsley, CEO of Ace Vision Group.
  • "Professor Marshall has already been a valuable supporter on our journey, and we are thrilled that he is assuming an official position on our team to propel us forward as we introduce our ground-breaking ophthalmic laser therapeutic for the age-related vision loss that comes with presbyopia."

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

Retrieved on: 
Samstag, Februar 24, 2024
BTK, QPM, BID, AAAAI, Week, Omalizumab, TID, News, Prurigo nodularis, Asthma, Swelling, IgG4-related disease, Skin, Oral medicine, UAS7, Patient, CSU, Disease, Itch, LSM, ITT, American Academy, Pharmaceutical industry

Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.

Key Points: 
  • Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.
  • Significant reduction from baseline to week 12 in weekly urticaria activity score (UAS7) [LSM -17.95 vs -11.20, respectively; p=0.0116].
  • Significant reduction from baseline to week 12 in weekly hives severity score (HSS7) [LSM -8.31 vs -4.89; p
  • Rilzabrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Retrieved on: 
Mittwoch, Februar 21, 2024
Vamorolone, Catalyst Pharmaceuticals, NSAA, Safety, Prednisone, DMD, Growth, Duchenne muscular dystrophy, Neurology, Biomarker, BMI, Patient, LSM, JAMA Neurology, Pharmaceutical industry

Catalyst holds the exclusive rights to commercialize AGAMREE® (vamorolone) in North America.

Key Points: 
  • Catalyst holds the exclusive rights to commercialize AGAMREE® (vamorolone) in North America.
  • Based on the published study, Santhera has reported that the results of the VISION-DMD study support the long-term efficacy and safety profile of vamorolone and conclude that vamorolone was generally well tolerated, consistent with the 24-week study findings, as published previously in JAMA Neurology [2].
  • This study [VISION-DMD] was conducted to determine the efficacy and safety of vamorolone over 48 weeks and to study crossover participants (prednisone to vamorolone; placebo to vamorolone).
  • Improvements of motor outcomes seen with 6 mg/kg/d of vamorolone at 24 weeks of treatment were maintained to 48 weeks of treatment.

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology

Retrieved on: 
Mittwoch, Februar 14, 2024
Vamorolone, NSAA, Safety, Prednisone, DMD, Growth, Duchenne muscular dystrophy, Neurology, European, Biomarker, BMI, Patient, Disease, LSM, JAMA Neurology, Pharmaceutical industry

“Vamorolone is a dissociative corticosteroid that selectively binds to the glucocorticoid receptor and has shown similar efficacy and reduced safety concerns in comparison with prednisone in Duchenne muscular dystrophy (DMD) [3].

Key Points: 
  • “Vamorolone is a dissociative corticosteroid that selectively binds to the glucocorticoid receptor and has shown similar efficacy and reduced safety concerns in comparison with prednisone in Duchenne muscular dystrophy (DMD) [3].
  • This study [VISION-DMD] was conducted to determine the efficacy and safety of vamorolone over 48 weeks and to study crossover participants (prednisone to vamorolone; placebo to vamorolone).
  • There was an increase in BMI after 24 weeks of treatment that then stabilized for both vamorolone groups.
  • Improvements of motor outcomes seen with 6 mg/kg/d of vamorolone at 24 weeks of treatment were maintained to 48 weeks of treatment.

Ace Vision Group Names Val Kolesnitchenko, MD as Chief Scientific Officer

Retrieved on: 
Dienstag, Februar 13, 2024
Ophthalmology, Alcon, Research, FDA, Presbyopia, Ageing, Bausch & Lomb, Eye, Executive, Patient, Disease, Val, Science, Bausch, LSM, Medical device

BOSTON, Feb. 13, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye and presbyopia, announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer.

Key Points: 
  • BOSTON, Feb. 13, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye and presbyopia, announced that it has named Val Kolesnitchenko, MD , as Chief Scientific Officer.
  • "Dr. Kolesnitchenko has a strong foundation in both surgical and therapeutic ophthalmology, as well as highly developed interpersonal skills and industry relationships," said Dr. AnnMarie Hipsley, CEO of Ace Vision Group.
  • Val's assignment to the company as Chief Scientific Officer comes at a very timely period in the company's preparations for its medical device regulatory submissions.
  • "I look forward to working with Ace Vision Group on this revolutionary approach to presbyopia," said Dr. Kolesnitchenko.